Al-Sawaf O, et al. - Given a link between CKT (≥3 chromosomal aberrations) and poor prognosis in CLL, and longer progression-free survival (PFS) and higher overall response rate and rate of minimal residual disease negativity achieved with VenG (venetoclax plus obinutuzumab) vs ClbG (chlorambucil plus obinutuzumab) in treatment-naïve, elderly, unfit CLL patients, researchers prospectively assessed CKT in CLL patients who received a fixed-duration, chemotherapy-free regimen of VenG. Findings revealed a correlation of CKT (which can be seen often in older, treatment-naïve CLL patients) with CLL-International Prognostic Index high/very high risk; TP53 aberrations were not exhibited by two-thirds of these patients. A shorter PFS and overall survival was reported in relation to CKT in patients who received ClbG, including those without TP53 aberrations. This adverse risk can be overcome by VenG. They concluded that chromosome analysis prior to frontline therapy is valuable, and VenG has benefits for CLL CKT patients.